Drug intelligence / Profile preview

BMS-919373

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-919373 is a selective, potent IKur current blocker developed by Bristol-Myers Squibb. It was investigated for the treatment of atrial fibrillation, acute coronary syndromes, and paroxysmal atrial fibrillation. The drug acts by inhibiting the Kv1.5 potassium channel, which is encoded by the KCNA5 gene and predominantly expressed in the atrium of humans.

Targets

KCNA5 (Ultra-rapid delayed rectifier potassium channel)

Beyond the preview

Go deeper on BMS-919373.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-919373.

Explore the full profile